{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-10.97","upperLimit":"18.55","value":"-0.22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"A test dose of IV busulfan 0.8 mg/kg was infused at Baseline (Day -12 to -9) to verify a target busulfan integrated AUC of 20,000 μM\\*min with a range of 16,000 to 24,000. If necessary the dose could be adjusted. The PK-directed dose recommendation based on the test dose was administered at Day -5. Blood samples for PK analysis were collected at 0, 15, 30 minutes after the End of Infusion and 240, 300, 360 minutes after start of the infusion. GC-MS was used to determine the busulfan level in plasma. The percent difference was calculated between AUC and the Target AUC.","dispersionType":"Full Range","groups":[{"description":"Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.","id":"OG000","title":"IV Busulfan"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population included all participants who received the PK-directed IV busulfan followed by autologous HSCT.","reportingStatus":"POSTED","timeFrame":"Baseline (Day -12 to -9), Day -5","title":"Percent Difference Between Area Under Curve (AUC) and Target AUC","type":"SECONDARY","unitOfMeasure":"Percent difference"}